Bradmer Pharmaceuticals
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Bradmer Pharmaceuticals
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
Tubulis Touts Transatlantic Plans As Cash Rolls In
The German biotech is benefitting from the heat in the antibody-drug conjugate space and has concluded an upsized series B2 financing for €128m.
The Impossible Task Of Regulating AI In Life Sciences
With specific and enforceable regulations for artificial intelligence in the life sciences unlikely anytime soon, companies need to follow their own ethical principles.
Company Information
- Industry
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice